RAPA-201 cell therapy for certain advanced lung and head cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) with cancer that has spread, returned, or cannot be removed by surgery
- Your health status is good enough to do daily activities (ECOG 0–2)
- Your tumor must be one of these: head and neck cancer, melanoma, small cell lung cancer, or non-small cell lung cancer
- You’ve already tried at least one prior treatment, including an anti–PD-1/PD-L1 antibody, and it didn’t work
- You have enough immune cells to make the therapy (blood lymphocytes at least 300 per microliter)
- Your recent treatments and side effects are sufficiently “cleared” (typically at least 2 weeks from chemo/surgery/radiation, and side effects are mild—grade 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to standard immunotherapy. It uses your own immune cells to fight the cancer.
This is an early-stage trial testing a new drug called CRPA1A2 that trains your immune cells to fight certain cancers. The drug targets tumors that have specific genetic markers (MAGE-A1 and HLA-A*02:01). You may qualify if you have advanced cancer that hasn't responded to standard treatments.
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a treatment for stage 3 lung cancer that cannot be removed with surgery. It includes people who have had other treatments before, like chemo or immunotherapy.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.